Your browser is no longer supported. Please, upgrade your browser.
MYGN Myriad Genetics, Inc. daily Stock Chart
Myriad Genetics, Inc.
Index- P/E- EPS (ttm)-1.99 Insider Own0.50% Shs Outstand74.50M Perf Week7.99%
Market Cap1.01B Forward P/E28.05 EPS next Y0.48 Insider Trans0.00% Shs Float73.24M Perf Month12.91%
Income-148.30M PEG- EPS next Q-0.47 Inst Own93.50% Short Float15.01% Perf Quarter-6.30%
Sales760.80M P/S1.33 EPS this Y-95.70% Inst Trans-8.16% Short Ratio9.97 Perf Half Y-31.53%
Book/sh12.98 P/B1.03 EPS next Y442.90% ROA-9.60% Target Price15.57 Perf Year-47.53%
Cash/sh2.40 P/C5.59 EPS next 5Y8.10% ROE-14.10% 52W Range9.24 - 35.29 Perf YTD-50.86%
Dividend- P/FCF19.13 EPS past 5Y-51.50% ROI0.90% 52W High-62.91% Beta1.43
Dividend %- Quick Ratio2.90 Sales past 5Y1.80% Gross Margin73.70% 52W Low41.67% ATR0.56
Employees2600 Current Ratio3.10 Sales Q/Q-24.30% Oper. Margin-22.20% RSI (14)60.84 Volatility4.85% 4.55%
OptionableYes Debt/Eq0.23 EPS Q/Q- Profit Margin-19.50% Rel Volume4.79 Prev Close13.38
ShortableYes LT Debt/Eq0.23 EarningsAug 13 AMC Payout- Avg Volume1.10M Price13.09
Recom3.10 SMA207.28% SMA505.77% SMA200-29.89% Volume431,640 Change-2.17%
Sep-26-19Downgrade BofA/Merrill Neutral → Underperform $30 → $28
Aug-14-19Downgrade Piper Jaffray Overweight → Neutral $45 → $40
Aug-02-19Upgrade BofA/Merrill Underperform → Neutral
Aug-01-19Upgrade Barclays Underweight → Equal Weight $18 → $40
Jul-29-19Downgrade Needham Strong Buy → Hold
Jul-09-19Downgrade Cowen Outperform → Market Perform
Mar-12-19Reiterated Needham Strong Buy $37 → $41
Jan-03-19Initiated Needham Strong Buy $36
Nov-30-18Upgrade Goldman Sell → Neutral
Oct-10-18Upgrade Piper Jaffray Neutral → Overweight
Jul-11-18Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-21-18Upgrade Morgan Stanley Underweight → Equal-Weight
Jan-29-18Initiated Goldman Sell $32
Jan-22-18Reiterated Barclays Equal Weight $30 → $35
Jan-05-18Initiated BTIG Research Buy $41
Oct-02-17Resumed Leerink Partners Mkt Perform $31
Aug-09-17Reiterated Barclays Equal Weight $28 → $26
Feb-08-17Upgrade Ladenburg Thalmann Sell → Neutral
Jan-18-17Initiated Deutsche Bank Sell $15
Oct-10-16Downgrade Ladenburg Thalmann Neutral → Sell
Aug-14-20 06:36AM  
Aug-13-20 06:15PM  
Aug-12-20 11:01AM  
Aug-10-20 07:05AM  
Aug-06-20 07:05AM  
Aug-04-20 12:30PM  
Jul-31-20 07:05AM  
Jul-29-20 07:05AM  
Jul-28-20 07:05AM  
Jul-22-20 07:05AM  
Jul-07-20 06:32PM  
Jul-06-20 10:04AM  
Jul-05-20 08:56PM  
Jul-02-20 08:46AM  
Jul-01-20 07:05AM  
Jun-29-20 11:27AM  
Jun-25-20 07:05AM  
Jun-23-20 11:19AM  
Jun-22-20 10:32AM  
Jun-17-20 11:53AM  
Jun-15-20 07:05AM  
Jun-12-20 07:48PM  
Jun-11-20 02:22PM  
Jun-09-20 10:23AM  
Jun-08-20 07:05AM  
Jun-05-20 09:00AM  
Jun-04-20 11:31AM  
May-29-20 07:05AM  
May-28-20 07:05AM  
May-27-20 11:14AM  
May-26-20 09:27AM  
May-20-20 08:12AM  
May-18-20 11:55AM  
May-13-20 05:26PM  
May-11-20 07:05AM  
May-06-20 11:49AM  
May-05-20 11:01PM  
Apr-28-20 04:05PM  
Apr-20-20 07:05AM  
Apr-08-20 07:05AM  
Apr-07-20 11:35AM  
Apr-06-20 07:05AM  
Mar-30-20 07:05AM  
Mar-23-20 07:13AM  
Mar-19-20 09:46AM  
Mar-18-20 07:05AM  
Mar-07-20 11:31AM  
Mar-04-20 08:29AM  
Mar-03-20 09:28AM  
Feb-28-20 06:58AM  
Feb-17-20 04:02PM  
Feb-14-20 07:05AM  
Feb-13-20 10:36AM  
Feb-12-20 07:05AM  
Feb-11-20 07:05AM  
Feb-07-20 08:08PM  
Feb-06-20 06:15PM  
Jan-30-20 07:05AM  
Jan-28-20 12:31PM  
Jan-22-20 06:36PM  
Jan-21-20 07:05AM  
Jan-14-20 07:05AM  
Jan-07-20 09:35AM  
Jan-06-20 04:05PM  
Dec-31-19 11:12AM  
Dec-30-19 04:29PM  
Dec-24-19 10:11AM  
Dec-23-19 06:18PM  
Dec-19-19 10:22PM  
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests worldwide. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lambert NicolePresident, MGLFeb 12Sale19.734,35485,91559,150Feb 12 06:28 PM
Ford AlexanderPresident, MWHFeb 05Sale30.007,273218,190142,438Feb 07 02:39 PM
Ford AlexanderPresident, MWHDec 26Option Exercise15.981,30720,886149,711Dec 27 12:47 PM
GILBERT WALTER PHDDirectorDec 13Buy25.605,860149,99854,150Dec 16 04:16 PM
HENDERSON JOHN TDirectorNov 07Buy23.461,75041,0562,050Nov 07 01:05 PM
HENDERSON JOHN TDirectorNov 07Buy23.465,250123,16764,353Nov 07 01:05 PM